Crucell Announces PER.C6 Commercial Licensing Agreement with ADImmune Corporation
16-Oct-2006
Under the terms of the agreement, ADImmune will pay a license issuance fee, annual maintenance fees and royalties on future product sales. Further financial details were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.